NCT05522387 2026-02-27An Open-Label Extension of XPro1595 in Patients With Alzheimer's DiseaseInmune Bio, Inc.Phase 2 Terminated11 enrolled
NCT06377033 2025-07-20Using the EHR to Advance Genomic Medicine Across a Diverse Health SystemUniversity of PennsylvaniaPhase NA Recruiting1,000 enrolled
NCT04971733 2025-06-10A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's DiseaseEisai Inc.Phase 1/2 Completed8 enrolled 21 charts
NCT05321498 2023-09-28Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of InflammationInmune Bio, Inc.Phase 2 Withdrawn